vs
Side-by-side financial comparison of APPFOLIO INC (APPF) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $262.2M, roughly 1.1× APPFOLIO INC). APPFOLIO INC runs the higher net margin — 16.2% vs -45.7%, a 61.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 20.4%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 15.3%).
AppFolio, Inc. is an American company founded in 2006 that offers software-as-a-service (SaaS) applications and services to the real estate industry.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
APPF vs GH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $262.2M | $281.3M |
| Net Profit | $42.4M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 19.4% | -43.0% |
| Net Margin | 16.2% | -45.7% |
| Revenue YoY | 20.4% | 39.4% |
| Net Profit YoY | 35.2% | -15.8% |
| EPS (diluted) | $1.18 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $262.2M | — | ||
| Q4 25 | $248.2M | $281.3M | ||
| Q3 25 | $249.4M | $265.2M | ||
| Q2 25 | $235.6M | $232.1M | ||
| Q1 25 | $217.7M | $203.5M | ||
| Q4 24 | $203.7M | $201.8M | ||
| Q3 24 | $205.7M | $191.5M | ||
| Q2 24 | $197.4M | $177.2M |
| Q1 26 | $42.4M | — | ||
| Q4 25 | $39.9M | $-128.5M | ||
| Q3 25 | $33.6M | $-92.7M | ||
| Q2 25 | $36.0M | $-99.9M | ||
| Q1 25 | $31.4M | $-95.2M | ||
| Q4 24 | $102.7M | $-111.0M | ||
| Q3 24 | $33.0M | $-107.8M | ||
| Q2 24 | $29.7M | $-102.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | 19.4% | — | ||
| Q4 25 | 17.6% | -43.0% | ||
| Q3 25 | 14.1% | -37.3% | ||
| Q2 25 | 17.2% | -45.9% | ||
| Q1 25 | 15.5% | -54.6% | ||
| Q4 24 | 11.3% | -62.4% | ||
| Q3 24 | 20.7% | -61.3% | ||
| Q2 24 | 18.3% | -56.8% |
| Q1 26 | 16.2% | — | ||
| Q4 25 | 16.1% | -45.7% | ||
| Q3 25 | 13.5% | -35.0% | ||
| Q2 25 | 15.3% | -43.0% | ||
| Q1 25 | 14.4% | -46.8% | ||
| Q4 24 | 50.4% | -55.0% | ||
| Q3 24 | 16.0% | -56.3% | ||
| Q2 24 | 15.0% | -57.9% |
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.10 | $-1.01 | ||
| Q3 25 | $0.93 | $-0.74 | ||
| Q2 25 | $0.99 | $-0.80 | ||
| Q1 25 | $0.86 | $-0.77 | ||
| Q4 24 | $2.79 | $-0.90 | ||
| Q3 24 | $0.90 | $-0.88 | ||
| Q2 24 | $0.81 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.4M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $470.2M | $-99.3M |
| Total Assets | $580.6M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $147.4M | — | ||
| Q4 25 | $107.0M | $378.2M | ||
| Q3 25 | $76.1M | $580.0M | ||
| Q2 25 | $73.5M | $629.1M | ||
| Q1 25 | $56.9M | $698.6M | ||
| Q4 24 | $42.5M | $525.5M | ||
| Q3 24 | $62.4M | $585.0M | ||
| Q2 24 | $59.6M | $933.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $470.2M | — | ||
| Q4 25 | $542.6M | $-99.3M | ||
| Q3 25 | $498.9M | $-354.5M | ||
| Q2 25 | $455.6M | $-305.5M | ||
| Q1 25 | $462.1M | $-250.8M | ||
| Q4 24 | $519.3M | $-139.6M | ||
| Q3 24 | $412.8M | $-60.1M | ||
| Q2 24 | $371.4M | $-1.6M |
| Q1 26 | $580.6M | — | ||
| Q4 25 | $689.0M | $2.0B | ||
| Q3 25 | $640.5M | $1.3B | ||
| Q2 25 | $567.4M | $1.3B | ||
| Q1 25 | $564.7M | $1.3B | ||
| Q4 24 | $626.7M | $1.5B | ||
| Q3 24 | $523.3M | $1.5B | ||
| Q2 24 | $479.3M | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.3M | — | ||
| Q4 25 | $65.0M | $-26.4M | ||
| Q3 25 | $86.0M | $-35.4M | ||
| Q2 25 | $52.6M | $-60.3M | ||
| Q1 25 | $38.5M | $-62.7M | ||
| Q4 24 | $36.6M | $-64.5M | ||
| Q3 24 | $57.8M | $-51.1M | ||
| Q2 24 | $50.9M | $-94.0M |
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $-54.2M | ||
| Q3 25 | $84.7M | $-45.8M | ||
| Q2 25 | $52.4M | $-65.9M | ||
| Q1 25 | $38.2M | $-67.1M | ||
| Q4 24 | $36.4M | $-83.4M | ||
| Q3 24 | $57.4M | $-55.3M | ||
| Q2 24 | $50.8M | $-99.1M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | -19.3% | ||
| Q3 25 | 34.0% | -17.3% | ||
| Q2 25 | 22.2% | -28.4% | ||
| Q1 25 | 17.6% | -33.0% | ||
| Q4 24 | 17.9% | -41.3% | ||
| Q3 24 | 27.9% | -28.9% | ||
| Q2 24 | 25.8% | -55.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 9.9% | ||
| Q3 25 | 0.5% | 3.9% | ||
| Q2 25 | 0.1% | 2.4% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.1% | 9.4% | ||
| Q3 24 | 0.2% | 2.2% | ||
| Q2 24 | 0.0% | 2.9% |
| Q1 26 | 0.81× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 2.56× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 1.75× | — | ||
| Q2 24 | 1.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
